Home / Market News / $PGEN
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Citizens Raises Precigen Price Target Following Q3 Results

Nov 6, 2026, 2:03 PM UTC · Primary ticker $PGEN

Citizens raised its price target for Precigen shares to $12 from $11, maintaining a 'Market Outperform' rating. This action follows Precigen's Q3 2026 financial results, which surpassed Wall Street revenue estimates, driven by strong sales of its PAPZIMEOS therapy.

Citizens, an investment firm, increased its price target for Precigen (PGEN) shares from $11 to $12 while reiterating its 'Market Outperform' rating. This positive analyst action stems from Precigen's strong third-quarter 2026 financial results, which exceeded revenue expectations. The primary driver for this outperformance was the robust sales momentum of its PAPZIMEOS therapy. For traders, this indicates continued positive sentiment and potential upside for PGEN in the short to medium term, as analyst upgrades often provide a boost to stock prices, reflecting confidence in the company's growth trajectory and product success.

$PGEN positive Price target increase and maintained outperform rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.